[1]刘合亮,林煜,郑世雄,等.青娥丸调控PERK/eIF2α/ATF4/CHOP通路对成骨细胞凋亡的影响[J].福建医药杂志,2025,47(03):66-71.[doi:10.20148/j.fmj.2025.03.017]
　LIU Heliang,LIN Yu,ZHENG Shixiong,et al.Mechanism of Qing'E formula regulating PERK/eIF2α/ATF4/CHOP pathway and its impact on osteoblast apoptosis[J].FUJIAN MEDICAL JOURNAL,2025,47(03):66-71.[doi:10.20148/j.fmj.2025.03.017]
点击复制

青娥丸调控PERK/eIF2α/ATF4/CHOP通路对成骨细胞凋亡的影响()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
47
期数:
2025年03期
页码:
66-71
栏目:
基础研究
出版日期:
2025-03-20

文章信息/Info

Title:
Mechanism of Qing'E formula regulating PERK/eIF2α/ATF4/CHOP pathway and its impact on osteoblast apoptosis
文章编号:
1002-2600(2025)03-0066-06
作者:
刘合亮; 林煜; 郑世雄; 肖莉莉
福建省福州市第二总医院,福州 350007
Author(s):
LIU Heliang;  LIN Yu;  ZHENG Shixiong;  XIAO Lili
Department of Orthopedics, Fuzhou Second General Hospital, Fuzhou, Fujian 350007, China
关键词:
绝经后骨质疏松症;  青娥丸;  内质网应激;  PERK/eIF2α/ATF4/CHOP信号通路
Keywords:
postmenopausal osteoporosis;  Qing'E formula;  endoplasmic reticulum stress;  PERK/eIF2α/ATF4/CHOPsignaling pathway
分类号:
R816.8
DOI:
10.20148/j.fmj.2025.03.017
文献标志码:
A
摘要:
目的 基于PERK/eIF2α/ATF4/CHOP信号通路探讨青娥丸含药血清对氧化应激诱导内质网应激凋亡成骨细胞系的保护作用及其作用机制。方法 30只雄性SD大鼠随机分为生理盐水组和青娥丸组,每组15只,分别给予生理盐水和青娥丸灌胃干预,连续7 d,腹主动脉取全血制备含药血清; 培养UMR-106细胞株,CCK-8筛选青娥丸和GSK2606414最佳干预浓度,细胞分为空白组、模型组、青娥丸组和抑制剂组,进一步采用10 μmol/L的H2O2干预细胞12 h制备内质网应激模型,CCK-8检测4组细胞的增殖活性,DCFH-DA检测细胞活性氧(ROS)含量,Real-time PCR和Western blot检测PERK、eIF2α、ATF4、CHOP mRNA和蛋白的相对表达量。结果 青娥丸含药血清最佳干预浓度为10%,GSK2606414最佳干预浓度为4%,此最佳干预浓度用于后续实验。H2O2干预后模型组细胞增殖活性显著降低,ROS含量显著升高,PERK、eIF2α、ATF4、CHOP mRNA和蛋白的相对表达量显著上调; 青娥丸组增殖活性增强,ROS含量显著降低,PERK、eIF2α、ATF4、CHOP mRNA和蛋白的相对表达量下调。结论 青娥丸含药血清可有效抑制成骨细胞系的内质网应激凋亡,其作用机制可能与PERK/eIF2α/ATF4/CHOP信号通路相关。
Abstract:
Objective To examine the protective effects and its mechanism of Qing'E formula serum on osteoblast apoptosis caused by oxidative stress-induced endoplasmic reticulum stress, focusing on the PERK/eIF2α/ATF4/CHOP signaling pathway. Methods Thirty male SD rats were randomly assigned to receive either normal saline or Qing'E formula via gavage for seven days to prepare drug-containing serum from abdominal aorta blood. UMR-106 cells were cultured, CCK-8 was selected for the optimal intervention concentration of Qing'E formula and GSK2606414. Cells were categorized into blank, model, Qing'E formula, and positive drug groups. The endoplasmic reticulum stress model was created by treating cells with 10 μmol/L H2O2 for 12 hours. Cell proliferation was assessed using CCK-8, ROS levels were dectected with DCFH-DA, and the expression levels of PERK, eIF2α, ATF4, and CHOP mRNA and protein were detected through Real-time PCR and Western blot. Results The optimal concentrations for Qing'E formula serum and GSK2606414 were found to be 10% and 4%, respectively. This optimal intervention concentration was used for subsequent experiments. Post-H2O2 treatment, the model group showed reduced cell proliferation, increased ROS, and elevated PERK, eIF2α, ATF4, and CHOP expression. Conversely, the Qing'E formula group exhibited increased proliferation, reduced ROS, and decreased expression of the above related markers. Conclusion Qing'E formula serum effectively inhibits endoplasmic reticulum stress-induced apoptosis in osteoblasts, possibly through the PERK/eIF2α/ATF4/CHOP signaling pathway.

参考文献/References:

[1] Silverstein W K,Cantor N,Cheung A M.Postmenopausal osteoporosis[J].N Engl J Med,2024,390(7):673-674.
[2] Zhao F,GuoChandran M.AACE/ACE clinical practice guide-lines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update:risk stratification and intervention thresholds[J].Endocr Pract,2021,27(4):378.
[3] Zhao F,Guo L,Wang X,et al.Correlation of oxidative stress-related biomarkers with postmenopausal osteoporosis:a systematic review and meta-analysis[J].Arch Osteoporos,2021,16(1):4.
[4] Tao H,Ge G,Liang X,et al.ROS signaling cascades:dual regulations for osteoclast and osteoblast[J].Acta Biochim Biophys Sin(Shanghai),2020,52(10):1055-1062.
[5] 李超,赵剑波,陈俊雅,等.金天格胶囊对H2O2诱导的小鼠成骨细胞MC3T3-E1氧化应激损伤及炎症因子的作用[J].中国骨质疏松杂志,2022,28(10):1448-1452,1532.
[6] 徐昊.雌激素对小鼠成骨细胞MC3T3-E1氧化应激损伤的保护作用及机制探究[J].中国实验动物学报,2020,28(6):824-830.
[7] 蒋华,韩岩峰,罗琳,等.白藜芦醇对绝经后骨质疏松女性骨代谢和氧化代谢产物水平的影响[J].中国骨质疏松杂志,2019,25(4):523-527.
[8] 陈帆,魏戌,崔鑫,等.青娥丸治疗绝经后骨质疏松症的系统评价及Meta分析[J].中国骨质疏松杂志,2021,27(2):179-189.
[9] Xiong J L,Cai X Y,Zhang Z J,et al.Elucidating the estrogen-like effects and biocompatibility of the herbal components in the Qing'E formula[J].J Ethnopharmacol,2022,283:114735.
[10] 王晓燕,常时新,李冠武,等.经方青娥丸对去势大鼠骨质疏松作用机制的实验研究[J].中国骨质疏松杂志,2017,23(2):197-202.
[11] 翁泽斌,颜翠萍,张志杰,等.不同炮制品入药的青娥丸含药血清对人成骨细胞增殖、分化及矿化的影响[J].中国实验方剂学杂志,2015,21(6):165-168.
[12] 范晓茜,陈锋,杨文娜.基于系统药理学和分子对接探讨青娥丸治疗绝经后骨质疏松症的作用机制[J].中国骨质疏松杂志,2021,27(5):735-741.
[13] 邸学士,陈昭,贾育松,等.基于网络药理学探讨青娥丸治疗绝经后骨质疏松症的作用机制[J].中国骨质疏松杂志,2021,27(3):364-371.
[14] 陈赛楠,周芬,黄云梅,等.基于PERK/eIF2α/ATF4/CHOP通路探讨健骨颗粒对UMR-106细胞内质网应激凋亡的影响[J].康复学报,2024,34(1):34-43.
[15] 夏雪,马陈,沈霖,等.古方青娥丸治疗绝经后骨质疏松症的临床疗效观察[J].中国中医骨伤科杂志,2016,24(7):20-22.
[16] 王欣燕,刘建红,黄显元.青娥丸对绝经后骨质疏松症患者骨密度、骨代谢指标和骨硬化蛋白的影响[J].中国骨质疏松杂志,2020,26(3):412-415.
[17] 刘玲,翁泽斌,王恒,等.青娥丸方有效成分药动学-药效学相关性研究[J].中国中药杂志,2016,41(23):4436-4441.
[18] 杨荣平,邓改改,罗友成,等.青娥丸不同萃取部位对成骨细胞增殖分化及破骨细胞活性的影响[J].时珍国医国药,2011,22(11):2588-2590.
[19] Zhang C,Li H,Li J,et al.Oxidative stress:a common pathological state in a high-risk population for osteoporosis[J].Biomed Pharmacother,2023,163:114834.
[20] 林锐钿,李子涵,古丽莎.内质网应激在骨代谢及其稳态中的作用[J].中华口腔医学研究杂志(电子版),2021,15(5):309-313.
[21] Wei J,Sheng X,Feng D,et al.PERK is essential for neonatal skeletal development to regulate osteoblast proliferation and differentiation[J].J Cell Physiol,2008,217(3):693-707.
[22] Saito A,Ochiai K,Kondo S,et al.Endoplasmic reticulum stress response mediated by the PERK-eIF2(alpha)-ATF4 pathway is involved in osteoblast differentiation induced by BMP2[J].J Biol Chem,2011,286(6):4809-4818.

相似文献/References:

[1]林建立,林移婷,陈耀琦,等.绝经后骨质疏松患者骨代谢与脂代谢的关系及血清蛋白组学研究[J].福建医药杂志,2025,47(02):1.[doi:10.20148/j.fmj.2025.02.001]
　LIN Jianli,LIN Yiting,CHEN Yaoqi,et al.Serum proteomics study on the relationship between bone metabolism and lipid metabolism in postmenopausal osteoporosis[J].FUJIAN MEDICAL JOURNAL,2025,47(03):1.[doi:10.20148/j.fmj.2025.02.001]

备注/Memo

备注/Memo:
基金项目:福州市卫健系统科技计划项目(2021-S-wq20); 福建省科学自然基金项目(2022J011318); 福建省卫生健康中青年骨干人才培养项目(2020GGB046); 福建省科技创新平台项目(福建省创伤骨科急救与康复临床医学研究中心,2020Y2014)
通信作者:郑世雄,Email:876514145@qq.com
更新日期/Last Update: 2025-03-20